HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women.
Vogelvang
T E
TE
Leurs
J R
JR
Mijatovic
V
V
Willemse
J
J
van der Mooren
M J
MJ
D025901:Carboxypeptidase B2 / Q000096:biosynthesis*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D015337:Multicenter Studies as Topic; D016017:Odds Ratio; D010919:Placebos; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000378:metabolism*; D012306:Risk; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*; D013997:Time Factors
C495287:HMR 3339; D010919:Placebos; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D004958:Estradiol; D025901:Carboxypeptidase B2